Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Study of Deucravacitinib for Refractory Adults With Dermatomyositis/ Juvenile Dermatomyositis

NCT07012057 is registered in ClinicalTrials.gov with National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) as lead sponsor.

NCT NCT07012057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07012057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Study of Deucravacitinib for Refractory Adults With Dermatomyositis/ Juvenile Dermatomyositis
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phase
Phase 2
Overall status
Withdrawn
Start date
November 21, 2025
Completion date
November 21, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis, myositis